Skip to main content

Analyse von Ereigniszeiten — Teil I

  • Chapter
Methodik klinischer Studien

Part of the book series: Statistik und ihre Anwendungen ((STATIST))

  • 356 Accesses

Zusammenfassung

Als Kriterien zur Beurteilung der Wirksamkeit einer Therapie werden in immer verstärkterem Maße Zeiten bis zum Auftreten eines bestimmten Zielereignisses herangezogen. Dies kann die Überlebenszeit im wörtlichen Sinne, d.h. die Zeit vom Beginn einer Behandlung bis zum Tod sein oder etwa die Zeit bis zum Auftreten eines Re-Infarkts in einer Studie zur Behandlung von Infarktpatienten. In onkologischen Studien sind Zeiten bis zum Eintritt einer Remission, bis zum Auftreten eines Rezidivs oder die Zeit bis zur Progredienz der Krankheit von besonderem Interesse. Wir werden an einigen Stellen den allgemeineren Begriff der Ereigniszeiten verwenden und an anderen Stellen aus historischen Gründen den speziellen Begriff der Überlebenszeit synonym für ereignisfreie Zeiten gebrauchen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. British Journal of Cancer 1995; 72: 511–518.

    Article  Google Scholar 

  • Brookmeyer R, Crowley J. A confidence interval for the median survival tima. Biometrics 1982; 38: 29–41.

    Article  MATH  Google Scholar 

  • Bull K, Spiegelhalter DJ. Tutorial biostatistics: survival analysis in observational studies. Statistics in Medicine 1997, 16: 1041 —1074.

    Google Scholar 

  • Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall, 1984.

    Google Scholar 

  • Fleming TR, O’Fallon JR, O’Brien PC, Harrington DP. Modified Kolmogorov-Smirnov test procedures with applications to arbitrarily censored data Biometrics 1980; 36: 607–625.

    Article  MathSciNet  MATH  Google Scholar 

  • Fleming TR, Green SJ, Harrington DP. Considerations for monitoring and evaluating treatment effects in clinical trials. Controlled Clinical Trials 1984; 5: 55–66.

    Article  Google Scholar 

  • Gehan E. A generalized Wilcoxon test for comparing arbitrarily single censored samples. Biometrika 1965; 52: 203–223.

    MathSciNet  MATH  Google Scholar 

  • Gill R, Schumacher M. A simple test of the proportional hazards assumption. Biometrika 1987; 74: 289–300.

    Article  MATH  Google Scholar 

  • Greenwood M. The natural duration of cancer. Reports on Public Health and Medical Subjects 33, London: Her Majesty’s Stationery Office, 1–26, 1926.

    Google Scholar 

  • Hall WJ, Wellner JA. Confidence bands for a survival curve from censored data. Biometrika 1980; 67: 133–143.

    Article  MathSciNet  MATH  Google Scholar 

  • Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley, 1980.

    MATH  Google Scholar 

  • Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Journal of the American Statistical Association 1958; 53: 457–481.

    Article  MathSciNet  MATH  Google Scholar 

  • Kay R, Schumacher M. Unibased assessment of treatment effects on disease recurrence and survival in clinical trials. Statistics in Medicine 1983; 2: 41–58.

    Article  Google Scholar 

  • Marubini E, Valsecchi MG. Analyising survival data from clinical trials and observational studies. Chichester: Wiley, 1994.

    Google Scholar 

  • Parmar MKB, Machin D. Survival analysis: a practical approach. Chichester: Wiley, 1995.

    MATH  Google Scholar 

  • Peto R, Peto J. Asymptotically efficient rank invariant test procedures (with discussion). Journal of the Royal Statistical Society (A) 1972; 135–206.

    Google Scholar 

  • Peto R, Pike, MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG. Design and analysis of clinical trials requiring prolonged observation of each patient. British Journal of Cancer, Part I 1976; 34: 585–612; Part II 1977; 35: 1–39.

    Google Scholar 

  • Prentice RL. Linear rank tests with right censored data. Biometrika 1978, 63, 291–298.

    MathSciNet  Google Scholar 

  • Schumacher M. Power and sample size determiation in survival time studies with special regard to the censoring mechanism. Meth. Inform. Med. 1981; 20: 110–115.

    Google Scholar 

  • Schumacher M. Evaluation of nonproportional treatment effects in cancer clinical trials. Cancer Investigation 1988; 6.

    Google Scholar 

  • Schumacher M, Olschewski M, Schmoor C. The impact of heterogeneity on the comparison of survival times. Statistics in Medicine 1987; 6: 773–784.

    Article  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schumacher, M., Olschewski, M. (2002). Analyse von Ereigniszeiten — Teil I. In: Methodik klinischer Studien. Statistik und ihre Anwendungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-08719-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-08719-0_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-43306-4

  • Online ISBN: 978-3-662-08719-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics